Iodine (124I) evuzamitide

Leveraging deep scientific and clinical expertise in MPNs to drive a pipeline of disease-modifying precision therapies that selectively target disease-driving cellsAdvancing AT-01, a first-in-class ADC programme, with strong preclinical validation towards IND/CTA-enabling studies, expected to begin in the first half of 2026AT-02 further expands ADC portfolio by targeting mutant CALR, a key MPN driver mutationLeadership and Board strengthened with appointments of Dr Rohit Batta as CEO and Mike Grey as Chair Oxford, UK - 30 October 2025 – Alethio Therapeutics, a biotech company advancing therapies designed to help people with Myeloproliferative Neoplasms (MPNs) live longer, healthier, and more fulfilling lives, today emerges from stealth with two antibody-drug conjugate (ADC) programmes and the appointments of Dr Rohit Batta as Chief Executive Officer and Mike Grey as Chair of the Board. Backed by deep scientific and clinical expertise, Alethio Therapeutics is focused on translating its discovery insights into a pipeline of precision, disease-modifying therapies. MPNs form a group of chronic, incurable and ultimately fatal blood cancers. Approximately 300,000 people in the US live with MPNs and existing approved therapies, such as JAK inhibitors, are largely symptomatic, meaning they do not eliminate the malignant cells or alter disease progression. Patients face premature death and severe quality-of-life impairment, and disease-modifying treatments are desperately needed. Leveraging deep expertise in MPNs to drive a pipeline of disease-modifying therapies Alethio Therapeutics brings decades of clinical expertise in MPNs and MPN biology from its founders, Professors Adam Mead and Beth Psaila from the University of Oxford. Alongside this, its powerful ARTEMIS discovery engine enables the Company to identify and validate novel targets, using access to one of the world’s largest MPN patient cell repositories, and to develop first-in-class medicines against these targets. ARTEMIS also enables Alethio Therapeutics to de-risk candidates before clinical trials using advanced human bone marrow organoid models that replicate patient biology. Advancing AT-01, a first-in-class ADC programme targeting disease-driving cells in MPN towards clinical proof of concept Alethio Therapeutic’s lead programme, AT-01, discovered and validated using ARTEMIS, is a first-in-class ADC designed and optimised to penetrate fibrotic bone marrow and target and eliminate disease-driving cells in MPN. AT-01 is based on a novel target, which is uniquely upregulated on disease-driving stem cells and fibrosis-driving megakaryocytes. AT-01 has demonstrated compelling disease-modifying potential in preclinical studies, with a favourable therapeutic index for MPNs, including: Potent selectivity and cytotoxicity in eliminating mutant stem cells while sparing healthy peripheral blood mononuclear cells (PBMCs) andReducing spleen size and fibrosis-driving cells, both predictive of improved clinical benefit Validation across multiple in vivo disease models, including founder-developed systems built over decades of research, as well as models using patient-derived cells in human bone marrow organoids that mimic the immunologically hostile myelofibrotic tumour microenvironment. Alethio Therapeutics’ goal is to shift MPN treatment from symptom control towards disease modification to meet a critical patient need. The Company is currently preparing AT-01 for IND/CTA-enabling studies, expected to begin in the first half of 2026. The Company is also advancing a second ADC programme AT-02, which targets mutant CALR and is undergoing preclinical evaluation. Mutant CALR is a major driver of MPN, found in ~30% of patients. It’s a standout target that is mutant-specific, surface-exposed, and ideal for an ADC therapeutic. Strengthened leadership and board driving Alethio Therapeutics’ focused strategy To drive Alethio Therapeutics’ discovery and development strategy in MPN, the Company today announces a strengthening and expansion of the leadership team and board with the appointments of Dr Rohit Batta as Chief Executive Officer and Mike Grey as Chair of the Board, succeeding Mark Throsby who remains on the board as a Non-Executive Director. Rohit Batta joins Alethio Therapeutics from Ferring Ventures, where he served as Managing Director and Head of the group company. Previously, he was Chief Medical Officer at Vicore Pharma and also held senior leadership roles at GSK, where he led the clinical strategy for haemoglobinopathy gene therapies and played a pivotal role in launching the world’s first gene therapy for a paediatric rare disease – an achievement that earned his team a prestigious Prix Galien award. Rohit brings 20 years of industry experience in translating breakthrough science into therapies and strategic partnerships. He began his career as a physician in the UK’s National Health Service, and has worked across multiple clinical specialties including oncology. Mike Grey is a seasoned leader with over 45 years of operational and board experience from biopharma, global pharma and venture capital. He has founded and grown several biotechnology companies and is currently Chair/Executive Chair of Mirum Pharmaceuticals, Sorriso Pharmaceuticals, Spruce Biosciences, Plexium and Theolytics. He also serves as Venture Partner with Pappas Capital. He joins Mark Throsby, Suman Shirodkar, and Beth Psaila on the Alethio Therapeutics Board. Mark Throsby is a biopharma executive and antibody engineering expert with leadership roles at Crucell, Merus, and Gadeta, and over 40 publications and multiple patents. Suman Shirodkar is a biotech leader with 25 years of experience, who led the European launch of Jakafi for MPN – contributing to its over $3B annual revenue – and most recently served as CEO of Larkspur Biosciences and Cambridge Epigenetix, and is Chair of NanoPhoria. Founding investor Oxford Science Enterprises is represented on the Board by Sally Dewhurst and Sanne De Jongh bringing significant experience in venture investing and company building based on cutting-edge science.Alethio Therapeutics is headquartered at Abingdon Science Park, near Oxford, with state-of-the-art labs supporting its growth and the delivery of key development milestones with AT-01 and across its pipeline. Formerly known as Alethiomics, the new company name marks the next chapter in Alethio Therapeutics evolution – from early scientific exploration to the development of disease-modifying precision medicines for MPNs. “With no curative options, MPNs expose patients to ongoing risk of disease evolution and poor outcomes,” said Rohit Batta, CEO. “Alethio Therapeutics is entering a new chapter with the ambition and team to deliver the first disease-modifying ADC therapies for MPNs. While current treatments are largely symptomatic, our unique expertise and approach enable us to directly target the drivers of disease progression, with the aim of shifting the treatment paradigm for MPNs and transforming outcomes for patients. It’s an exciting time to be joining Alethio Therapeutics, and I look forward to working with our founders, Beth Psaila and Adam Mead – leading MPN clinicians – our strategic board, and a talented team with deep expertise in cancer cell biology, organoid development, and bioinformatics, as we advance AT-01 and build our pipeline.” “Alethio Therapeutics is advancing its lead programme to the clinic, benefitting from the capabilities it has assembled for the creation of disease-modifying medicines for chronic blood cancers where existing treatments are inadequate,” added Mike Grey, Chair of the Board. “The Company combines a wealth of expertise around MPN disease biology and treatment, target discovery and ADC development, which has the potential to unlock untapped opportunities in MPNs and fuel a pipeline of disease-modifying precision therapies. I’d like to thank Mark Throsby for his leadership as Chair and look forward to working alongside him and the broader team as we execute our new, focused strategy.” ENDS Contacts Rohit Batta, CEO Alethio Therapeuticsrohit.batta@alethiomics.com Mark Swallow, Sandi Greenwood, MEDiSTRAVAAlethioTx@Medistrava.com Notes to Editors About Alethio TherapeuticsAlethio Therapeutics is pioneering the development of disease-modifying therapies for patients with chronic blood cancers, with the aim of helping them live fully, freely, and well. Formerly known as Alethiomics, Alethio Therapeutics is specifically focused on myeloproliferative neoplasms (MPNs), a group of chronic, incurable, and ultimately fatal blood cancers, where currently approved treatments – such as JAK inhibitors – are not selectively targeting disease-driving cells and primarily offer symptomatic relief. The Company’s lead programme, AT-01, is a first-in-class antibody drug conjugate (ADC) based on a novel target identified on MPN mutant stem cells that drive MPN disease progression. Alethio Therapeutics has generated compelling preclinical data for AT-01 demonstrating elimination of targeted cells, paving the way for IND-enabling studies in 2026. The Company is leveraging its expertise in MPN biology, bone marrow organoids, and ADC technology to advance AT-02, its second ADC candidate targeting mutant CALR – a key driver mutation in MPNs – currently in preclinical development. Alethio Therapeutics’ proprietary discovery engine, ARTEMIS, integrates access to leading MPN biobanks, single-cell sequencing, organoids, and bioinformatics to de-risk first-in-human trials and identify new mutant drivers, expanding therapeutic reach and market potential. Alethio Therapeutics is led by a highly experienced team and board, with Oxford Science Enterprises as its anchor investor. www.alethiotherapeutics.com About Oxford Science EnterprisesOxford Science Enterprises (OSE) is an independent, billion-pound investment company that finds, funds and builds transformational science and technology companies emerging from Oxford’s world-leading research. Our portfolio of companies is focused across three high-impact sectors – Deep Tech, Life Sciences, and HealthTech – with the ambition of tackling some of the world’s greatest challenges. To date, OSE has collaborated with over 300 international investors, collectively investing over £3 billion in more than 100 groundbreaking companies.https://www.oxfordscienceenterprises.com/ Attachments Rohit Batta Mike Grey

124I-evuzamitide, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis of cardiac amyloidosis in patients suspected of or diagnosed with cardiac amyloidosis in ATTR, AL, and other rare types of systemic amyloidosis. 124I-evuzamitide PET/MRI repeat imaging demonstrated consistency with clinical disease course over ~12 months in patients with cardiac amyloidosis Phase 3 REVEAL study with 124I-evuzamitide in patients with suspected cardiac amyloidosis is ongoing AT-05 (99mTc-p5+14), a pan-amyloid radiotracer, designed for SPECT imaging, demonstrated high levels of sensitivity and specificity for detection of cardiac amyloid in AL and ATTR patients NAPLES, Fla., Sept. 8, 2025 — Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines and diagnostics to improve the lives of patients with systemic amyloidosis, announced five poster presentations and two oral presentations (from investigator-initiated trials), on the use of 124I-evuzamitide and AT-05 (99mTc-p5+14) , the company’s pan-amyloid binding diagnostic imaging agents in development for the diagnosis of systemic amyloidosis, at the American Society of Nuclear Cardiology Annual Scientific Session & Exhibition (ASNC) held in Orlando, FL on September 4–7, 2025. “Diagnosing patients early remains one of the biggest unmet needs for systemic amyloidosis patients, with many going years without an accurate diagnosis.  Current diagnostic methods focus on transthyretin amyloidosis and may not accurately detect early infiltration of amyloid deposits,” said Ahmad Masri, M.D., Associate Professor of Medicine and Cardiomyopathy Section Head at Oregon Health & Science University. “In our PET/MR study, in 111 patients, we were able to show 100 percent sensitivity and specificity for detection of cardiac amyloid in ATTR, AL, and other rare types of systemic amyloidosis patients, including in very early patients. In addition, we demonstrated the ability of 124I-evuzamitide to detect extracardiac amyloid and to monitor changes in amyloid load over time with repeated measures. We have been impressed by the results to date and are very much looking forward to the results of the ongoing Phase 3 REVEAL study in suspected cardiac amyloidosis patients. We are excited by the potential of 124I-evuzamitide to become a new standard of care for diagnosing and monitoring of systemic amyloidosis.” “Detection and quantification of amyloid burden in the heart is an unmet clinical need for patients with diverse types of systemic amyloidosis,” said Jonathan Wall, Ph.D., Distinguished Professor, University of Tennessee Graduate School of Medicine. “AT-05 is a promising new reagent for the detection of ATTR and AL cardiac amyloid using planar gamma or SPECT imaging and may serve as a useful tool for the early detection of cardiac and extracardiac amyloid in the community setting for healthcare professionals that have limited access to PET imaging scanners. “We are excited about the promise of both 124I-evuzamitide and AT-05 to impact the lives of systemic amyloidosis patients by potentially diagnosing them earlier and more accurately than current standard of care. Patients receive the most benefit from new therapeutics if given early in the disease process and early diagnosis with 124I-evuzamitide could lead to better outcomes for patients. We are excited about the progress of the ongoing REVEAL phase 3 study and look forward to the results in early 2026,” said Spencer Guthrie, Chief Operating Officer, Attralus. Oral Presentations – Abstract Title: Diagnostic Performance of Cardiac and Whole-Body 124I-evuzamitide (AT-01) PET/MRI in Systemic Amyloidosis Presenter: Ahmad Masri, M.D., Oregon Health and Science University (OHSU) Date/Time: September 5, 2025, 4:45 – 5:45 p.m. EDT Key Findings: 111 patients were enrolled in the study. Of these, 77 had cardiac transthyretin amyloidosis, 22 had cardiac light chain amyloidosis, 3 had AApoAI or AApoAIV, 10 had systemic amyloidosis but no cardiac involvement, and 24 had no evidence of systemic amyloidosis. 124I-evuzamitide PET/MRI had 100% sensitivity and specificity in detecting cardiac amyloidosis in all amyloidosis types. No false positive or false negative cases were observed. Demonstrated evidence of extracardiac uptake in AL, ATTRv and ATTRwt patients, including the kidney, liver, lungs, spleen and musculoskeletal. Demonstrated evidence of 124I-evuzamitide uptake in biopsy proven ATTRwt patients with negative PYP bone scintigraphy and a cardiac MRI not suggestive of amyloid. 124I-evuzamitide was safe without any serious adverse events. Time from 124I-evuzamitide injection to whole-body PET was 3.3 ±0.5 hours. Abstract Title: A Tale of Two Tracers – A Qualitative Comparison of the PET and SPECT Amyloid-Imaging Agents, 124I-evuzamitide (AT-01) and 99mTc-p5+14 (AT-05), that are Derived from the Same Synthetic Amyloid-Binding Peptide, p5+14 Presenter: Jonathan S. Wall, University of Tennessee Graduate School of Medicine, Knoxville, TN Date/Time: September 5, 2025, 4:45 – 5:45 p.m. EDT Key Findings: 124I-evuzamitide and 99mTc-p5+14 are both novel amyloid-reactive peptide radiotracers enabling noninvasive detection of cardiac and systemic amyloid. PET/CT imaging with 124I-evuzamitide may yield higher resolution and quantitative data, whereas 99mTc-p5+14 imaging may prove to be simpler and more accessible. The PET tracer has demonstrated excellent sensitivity in clinical trials and is in a Phase 3 study, whereas the SPECT agent has shown promising early clinical results. Together, they serve as tools that offer complementary strengths: one for detailed quantification in specialized centers, the other for widespread screening and routine practice. 124I-evuzamitide and 99mTc-p5+14 are both novel amyloid-reactive peptide radiotracers enabling noninvasive detection of cardiac and systemic amyloid. PET/CT imaging with 124I-evuzamitide may yield higher resolution and quantitative data, whereas 99mTc-p5+14 imaging may prove to be simpler and more accessible. The PET tracer has demonstrated excellent sensitivity in clinical trials and is in a Phase 3 study, whereas the SPECT agent has shown promising early clinical results. Together, they serve as tools that offer complementary strengths: one for detailed quantification in specialized centers, the other for widespread screening and routine practice. Poster Presentations – Abstract Title: Temporal Changes in Cardiac Amyloidosis Using 124I-evuzamitide PET/MRI Imaging Presenter: Ahmad Masri, M.D., Oregon Health and Science University (OHSU) Date/Time: September 5, 2025, 3:45 – 4:45 p.m. EDT Key Findings: 21 patients (16 AL, 5 ATTR) had a 124I-evuzamitide PET/MRI baseline scan and a repeat scan ~ 12 months later. Patients were on standard of care therapy for cardiac amyloidosis. The change in mean Left Ventricular (LV) Standard uptake value ratio (SUVR) trended with the change in ECV and NT-proBNP but not LVM. The change in max LV SUVR trended with the change in ECV, NT-proBNP and LVM. Minimal clinical changes were observed in patients, which was well captured by stable 124I-evuzamitide uptake. 21 patients (16 AL, 5 ATTR) had a 124I-evuzamitide PET/MRI baseline scan and a repeat scan ~ 12 months later. Patients were on standard of care therapy for cardiac amyloidosis. The change in mean Left Ventricular (LV) Standard uptake value ratio (SUVR) trended with the change in ECV and NT-proBNP but not LVM. The change in max LV SUVR trended with the change in ECV, NT-proBNP and LVM. Minimal clinical changes were observed in patients, which was well captured by stable 124I-evuzamitide uptake. Abstract Title: Accurate Quantitation of Cardiac Amyloidosis by 124I-Evuzamitide Compared to Extracellular Volume Presenter: Alyssa de Moraes, Brigham and Women’s Hospital (BWH) Date/Time: September 4, 2025, 5:35 – 6:25 p.m. EDT Key Findings: 124I-evuzamitide PET/CT showed mild cardiac uptake and extensive hepatic uptakecontrasted with healthy control data Hepatic AL amyloidosis was diagnosed by international criteria of liver enlargement, elevated alkaline phosphatase (>1.5 times normal limits), and absence of heart failure in a patient with biopsy proven AL amyloidosis. This case underscores the value of ¹²⁴I-evuzamitide PET/CT, a novel pan-amyloid binding radiotracer, for diagnosing hepatic AL amyloidosis and avoiding organ biopsy. Abstract Title: Exploring cardiac uptake of the SPECT radiotracer, 99mTc-p5+14 (AT-05), in patients with amyloidosis – Significant correlations exist between structural or functional parameters and signal-to-background measurements. Presenter: R. Eric Heidel, University of Tennessee Graduate School of Medicine, Knoxville, TN Date/Time: September 5, 2025, 3:45 – 4:45 p.m. EDT Key findings: The 99mTc-p5+14 planar heart-to-lung uptake ratio in ATTR patients correlated significantly with NT-proBNP and global longitudinal strain measurements. Significant positive linear correlations were observed between the SPECT uptake ratio of 99mTc-p5+14 and the cardiac interventricular septum and left ventricular wall thickness, and serum NT-proBNP. The preliminary data supports further evaluation of 99mTc-p5+14 imaging for detecting cardiac amyloid and its relationship with other measures of amyloid-associated cardiac dysfunction. The 99mTc-p5+14 planar heart-to-lung uptake ratio in ATTR patients correlated significantly with NT-proBNP and global longitudinal strain measurements. Significant positive linear correlations were observed between the SPECT uptake ratio of 99mTc-p5+14 and the cardiac interventricular septum and left ventricular wall thickness, and serum NT-proBNP. The preliminary data supports further evaluation of 99mTc-p5+14 imaging for detecting cardiac amyloid and its relationship with other measures of amyloid-associated cardiac dysfunction. Abstract Title: Extracardiac uptake of the SPECT/CT imaging agent, 99mTc-p5+14 (AT-05), in patients with AL or ATTR cardiac amyloidosis Presenter: Emily B. Martin, University of Tennessee Graduate School of Medicine, Knoxville, TN Date/Time: September 5, 2025, 3:45 – 4:45 p.m. EDT Key Findings: No cardiac uptake of 99mTc- p5+14 was seen in healthy subjects (100% negative percent agreement; 5/5). Cardiac amyloid was readily imaged in patients with AL or ATTR amyloidosis (94% positive percent agreement; 15/16). In ATTR patients, 99mTc-p5+14 was observed in focal lesions and pleura of the lungs as well as joints. In patients with cardiac AL amyloidosis, tracer uptake was observed in the lung, liver, spleen, salivary glands, thyroid gland, and tongue. No cardiac uptake of 99mTc- p5+14 was seen in healthy subjects (100% negative percent agreement; 5/5). Cardiac amyloid was readily imaged in patients with AL or ATTR amyloidosis (94% positive percent agreement; 15/16). In ATTR patients, 99mTc-p5+14 was observed in focal lesions and pleura of the lungs as well as joints. In patients with cardiac AL amyloidosis, tracer uptake was observed in the lung, liver, spleen, salivary glands, thyroid gland, and tongue. Abstract Title: 99mTc-p5+14 (AT-05) is a pan-amyloid imaging agent that effectively detects cardiac amyloid by both planar and SPECT/CT imaging at 1 h post-injection with a high signal-to-background ratio Presenter: Jonathan S. Wall, University of Tennessee Graduate School of Medicine, Knoxville, TN Date/Time: September 5, 2025, 3:45 – 4:45 p.m. EDT Key Findings: Patients with cardiac amyloidosis had significant uptake of 99mTc-p5+14 in the heart, evidenced in planar and SPECT/CT images acquired at 1 h pi. No cardiac uptake of 99mTc-p5+14 was observed in healthy subjects. In planar images at 1 h pi, the heart:lung ratio for 99mTc-p5+14 was greater in patients versus healthy subjects (p<0.0001) and patient 99mTc-PYP images (p=0.0303). Cardiac uptake of 99mTc-p5+14 assessed from SPECT/CT images was significantly higher than that of 99mTc-PYP in ATTR patients (p=0.0009) and of 99mTc-p5+14 in healthy subjects (p<0.0001). Patients with cardiac amyloidosis had significant uptake of 99mTc-p5+14 in the heart, evidenced in planar and SPECT/CT images acquired at 1 h pi. No cardiac uptake of 99mTc-p5+14 was observed in healthy subjects. In planar images at 1 h pi, the heart:lung ratio for 99mTc-p5+14 was greater in patients versus healthy subjects (p<0.0001) and patient 99mTc-PYP images (p=0.0303). Cardiac uptake of 99mTc-p5+14 assessed from SPECT/CT images was significantly higher than that of 99mTc-PYP in ATTR patients (p=0.0009) and of 99mTc-p5+14 in healthy subjects (p<0.0001). For additional information, please visit the ASNC 2025 website.To view posters and presentations, visit the Attralus website. About 124I-evuzamitide (AT-01) Pan-Amyloid Diagnostic124I-evuzamitide is the first non-invasive pan-amyloid PET imaging agent specifically designed for systemic amyloidosis. 124I-evuzamitide utilizes the company’s pan-amyloid binding peptide labeled with iodine-124 as an amyloid-specific radiotracer to detect all types of systemic amyloidosis by PET/CT imaging. In clinical trials, 124I-evuzamitide has been observed to detect multiple types of amyloid deposits, including ATTR and AL, in major organs such as the heart, kidney, liver, and spleen. Orphan drug designations have been granted to 124I-evuzamitide as a diagnostic for the management of ATTR and AL amyloidosis by both the Food and Drug Administration (FDA) and the European Commission. About Phase 3 REVEAL StudyResearch with 124I-EVuzamitide to Elucidate Cardiac AmyLoidosis (REVEAL) study is an ongoing Phase 3 clinical trial of the investigational diagnostic imaging agent 124I-evuzamitide in patients with suspected cardiac amyloidosis by Brigham and Women’s Hospital in Boston, MA. The trial is designed to determine the sensitivity and specificity of 124I-evuzamitide imaging to diagnose cardiac amyloidosis. About AT-05, Pan-Amyloid DiagnosticAT-05 uses the same pan amyloid binding peptide as 124I-evuzamitide but is labelled with technetium-99m (Tc-99m, 99mTc). AT-05 is designed to be used with single-photon emission computerized tomography (SPECT) to be more accessible to community cardiologists and thereby support broader screening of systemic amyloidosis. AT-05 is currently in a Phase 1 clinical trial. About Systemic AmyloidosisSystemic amyloidosis encompasses a diverse group of rare diseases that occur due to accumulation of toxic amyloid deposits in tissues and organs, a consequence of aberrant protein misfolding events. These diseases are progressive, debilitating and often fatal. The majority of systemic amyloidosis patients have cardiac involvement, including the two most common forms, with ~95 percent of ATTR and 75% of AL patients having cardiac involvement. Other rare types of systemic amyloidosis such as AA, AApoAI, AApoAIV also have cardiac involvement. Cardiac amyloidosis is significantly underdiagnosed due to low awareness, non- specific symptoms, and lack of disease-specific diagnostics. There remains a significant unmet need for better diagnostics that may be able to more accurately diagnose patients earlier in the disease process. About AttralusAttralus is a clinical stage biopharmaceutical company focused on creating transformative medicines and diagnostics to improve the lives of patients with systemic amyloidosis. The company’s proprietary pan-amyloid removal (PAR) therapeutics are designed to directly bind to and remove toxic amyloid in organs and tissues. By targeting the disease-causing pathology in systemic amyloidosis diseases, PAR therapeutics have the potential to treat and reverse disease in patients with all types and stages of systemic amyloidosis. Attralus was founded by scientific experts in the field of amyloidosis and the company is headquartered in Naples, FL. Forward-Looking StatementsThis press release contains forward-looking statements, including statements related to the efficacy, continued development, and potential of 124I-evuzamitide and AT-05. Words such as “developing,” “potential,” “shown” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Attralus’ current expectations. Forward-looking statements involve risks and uncertainties. Attralus’ actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. Attralus expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Attralus’ expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. Contact:Krishna Gorti, M.D. FRCSCorporate Developmentkgorti@attralus.com ###